…
BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cellink AB (publ) develops and sells instruments, consumables and software for 3D bioprinting and life‑science research, including bioinks and laboratory automation tools used in tissue engineering and drug discovery. Long‑term growth may be supported by rising adoption of 3D models, greater demand for predictive preclinical testing and recurring consumables revenue as researchers and pharma expand in vitro workflows. Investors may find the company attractive because it appears positioned in a specialized, expanding niche with product-driven recurring revenues.
Key risks include intense competition from larger life‑science equipment suppliers, sensitivity to academic and pharmaceutical R&D budgets and capital spending cycles, regulatory and validation hurdles for new applications, and execution risk from integrating acquisitions and scaling manufacturing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-08-31 |
| Income before tax | -1573.44M | -70.60M | -797.30M | -753.10M | -753.10M |
| Minority interest | 4.20M | 3.60M | 1.10M | 2.80M | 2.80M |
| Net income | -1086.17M | -5.50M | -1172.70M | -832.90M | -832.90M |
| Selling general administrative | 303.50M | 552.30M | 986.20M | 719.00M | 719.00M |
| Selling and marketing expenses | - | 425.70M | - | - | - |
| Gross profit | 580.44M | 1007.30M | 993.30M | 1830.60M | 1830.60M |
| Reconciled depreciation | 1271.60M | 478.30M | 1144.20M | 940.60M | 940.60M |
| Ebit | -251.47M | -284.00M | - | -618.30M | -618.30M |
| Ebitda | -34.81M | -111.10M | - | 322.30M | 322.30M |
| Depreciation and amortization | 216.66M | 172.90M | - | 940.60M | 940.60M |
| Operating income | -251.47M | -289.10M | -293.30M | -996.90M | -996.90M |
| Other operating expenses | 1744.91M | 2235.40M | - | 3257.30M | 3257.30M |
| Interest expense | 321.59M | 97.60M | 95.90M | 98.20M | 98.20M |
| Tax provision | 6.40M | 23.10M | -8.60M | 82.60M | 82.60M |
| Interest income | 37.60M | 17.90M | 18.30M | 6.80M | 6.80M |
| Net interest income | -284.80M | -74.00M | -84.60M | -108.10M | -108.10M |
| Income tax expense | 6.38M | 23.10M | - | 82.60M | 82.60M |
| Total revenue | 1493.44M | 1946.30M | 2010.40M | 2239.50M | 2239.50M |
| Total operating expenses | 831.91M | 1296.40M | 2303.80M | 2848.40M | 2848.40M |
| Cost of revenue | 913.00M | 939.00M | 1017.20M | 408.90M | 408.90M |
| Total other income expense net | -1321.98M | 218.50M | - | 243.80M | 243.80M |
| Net income from continuing ops | -1583.70M | -93.70M | -788.70M | -835.70M | -835.70M |
| Net income applicable to common shares | - | - | - | -832.90M | -832.90M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-08-31 |
| Total assets | 3687.33M | 5483.20M | 7897.80M | 10196.80M | 10196.80M |
| Intangible assets | 519.50M | 825.80M | 1203.40M | 1439.20M | 1439.20M |
| Other current assets | 96.96M | 1459.95M | - | 0.10M | 0.10M |
| Total liab | 1943.01M | 2475.60M | 2989.90M | 3264.60M | 3264.60M |
| Total stockholder equity | 1744.21M | 2985.00M | 4907.90M | 6905.00M | 6905.00M |
| Deferred long term liab | - | - | - | 462.10M | 462.10M |
| Other current liab | 178.85M | 397.60M | 78.90M | 526.80M | 709.20M |
| Common stock | 1.80M | 1.80M | - | 1.80M | 1.80M |
| Capital stock | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M |
| Retained earnings | -5936.87M | -4861.80M | -3094.40M | -1106.60M | -1106.60M |
| Other liab | - | - | - | 569.70M | 569.70M |
| Good will | 775.20M | 2170.90M | 3822.80M | 5273.70M | 5273.70M |
| Other assets | - | - | - | 604.00M | 604.00M |
| Cash | 1278.98M | 598.00M | 804.10M | 925.20M | 925.20M |
| Total current liabilities | 1570.85M | 570.80M | 847.00M | 939.50M | 939.50M |
| Current deferred revenue | 256.65M | - | - | 594.80M | 594.80M |
| Net debt | 222.24M | 1165.40M | 618.20M | 927.90M | 927.90M |
| Short term debt | 1065.92M | 93.80M | - | 97.70M | 97.70M |
| Short long term debt | 1004.80M | 6.70M | 6.50M | 8.00M | 8.00M |
| Short long term debt total | 1501.22M | 1763.40M | - | 1853.10M | 1853.10M |
| Other stockholder equity | 7582.03M | 7845.00M | - | 8009.80M | 8009.80M |
| Property plant equipment | - | - | - | 901.60M | 901.60M |
| Total current assets | 2000.27M | 1854.30M | 2040.90M | 2437.00M | 2437.00M |
| Net tangible assets | - | - | - | 654.20M | 654.20M |
| Net receivables | 428.42M | 50.18M | 520.00M | 1018.60M | 1018.60M |
| Long term debt | 0.20M | 1337.10M | 1415.80M | 1384.90M | 1384.90M |
| Inventory | 195.91M | 259.00M | 405.20M | 493.10M | 493.10M |
| Accounts payable | 69.43M | 77.90M | 170.20M | 132.60M | 132.60M |
| Accumulated other comprehensive income | 97.26M | - | - | - | - |
| Non currrent assets other | -2.60M | 42.90M | -0.10M | 43.60M | 43.60M |
| Non current assets total | 1687.06M | 3628.90M | 5856.90M | 7759.80M | 7759.80M |
| Capital lease obligations | 281.90M | 419.60M | 536.00M | 460.20M | 460.20M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-08-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-08-31 |
| Investments | 5.50M | -4.10M | 189.70M | 212.90M | 212.90M |
| Change to liabilities | - | - | - | 0.00M | 0.00M |
| Total cashflows from investing activities | 707.52M | 128.00M | - | 212.90M | 212.90M |
| Net borrowings | -347.80M | -105.60M | -6.40M | -78.10M | -78.10M |
| Total cash from financing activities | -453.96M | -200.70M | - | 455.30M | 455.30M |
| Change to operating activities | - | - | - | 85.40M | 85.40M |
| Net income | -1575.64M | 8.10M | -1983.20M | -753.10M | -753.10M |
| Change in cash | 493.83M | 85.30M | 133.60M | 444.00M | 444.00M |
| Begin period cash flow | 785.15M | 861.00M | 378.70M | 481.20M | 481.20M |
| End period cash flow | 1278.98M | 946.30M | 680.50M | 925.20M | 925.20M |
| Total cash from operating activities | 68.23M | 158.40M | -72.10M | -269.40M | -269.40M |
| Issuance of capital stock | -0.20M | 3.60M | 493.00M | 540.60M | 540.60M |
| Depreciation | 216.66M | 478.30M | 1929.30M | 940.60M | 940.60M |
| Other cashflows from investing activities | - | -43.20M | - | 705.20M | - |
| Change to inventory | 15.96M | 92.20M | -122.10M | -162.10M | -162.10M |
| Change to account receivables | -1.90M | 124.10M | - | -189.40M | -189.40M |
| Other cashflows from financing activities | -106.83M | 3.28M | - | -81.00M | -81.00M |
| Change to netincome | - | - | - | 508.60M | 508.60M |
| Capital expenditures | 13.27M | 44.10M | 454.10M | 529.60M | 529.60M |
| Change in working capital | 112.52M | 48.60M | -110.60M | -266.10M | -266.10M |
| Stock based compensation | 3.20M | 2.10M | -20.10M | 39.00M | 39.00M |
| Other non cash items | 1314.69M | -378.70M | -113.50M | -229.80M | -229.80M |
| Free cash flow | 54.96M | 114.30M | -643.00M | -799.00M | -799.00M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLLKF Cellink AB (publ) |
- -% |
2.54 | - | - | 1.03 | 0.86 | 1.06 | 70.69 |
| ABT Abbott Laboratories |
-0.20 0.19% |
103.00 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.59 0.59% |
100.02 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
- -% |
310.00 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
48.34 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.
| Name | Title | Year Born |
|---|---|---|
| Mr. Erik Gatenholm | Co-Founder, CEO, Pres & Director | 1989 |
| Dr. Hector Martinez | Exec. VP, Co-Founder & CTO | 1985 |
| Mr. Mikael Engblom | Interim Chief Financial Officer | 1977 |
| Ms. Asa Hillsten | Sr. VP & Head of Investor Relations | 1975 |
| Lotta Bus | SVP, Gen. Counsel & Sec. | 1970 |
| Ms. Karin Danielsson | Global HR Director | 1982 |
| Ms. Erica Bell | Sr. VP & Chief People Officer | 1973 |
| Mr. Artur Aira | Sr. VP & Bus. Area Director - Bioprinting | 1967 |
| Ms. Itedale Namro Redwan | Chief Scientific Officer - Bioprinting | NA |
| Niclas Emanuelsson | Head of Global Operations | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.